文献速递产科麻醉

去氧肾上腺素与间羟胺输注预防剖宫产腰麻低血压的随机双盲试验

A randomised double-blind trial of phenylephrine and metaraminol infusions for prevention of hypotension during spinal and combined spinal-epidural anaesthesia for elective caesarean section.
PubMed 文献 · Anaesthesia · 2017-03-03

这项多中心随机双盲非劣效研究纳入185例择期剖宫产产妇,比较腰麻后立即启动的去氧肾上腺素(50 μg.min-1)与间羟胺(250 μg.min-1)预防性输注。主要结局为脐动脉pH组间差异,间羟胺组脐动脉pH高于去氧肾上腺素组,差异超过预设非劣效界值并达到优效标准;间羟胺组低血压更少,但高血压及重度高血压更多。

要点

  • 间羟胺输注在新生儿酸碱结局方面不劣于去氧肾上腺素,且达到优效标准
  • 去氧肾上腺素组低血压发生率更高,间羟胺组高血压及重度高血压发生率更高
  • 两组Apgar评分、恶心呕吐及产妇心动过缓发生率无显著差异

核心结论

  • 择期剖宫产腰麻后以间羟胺输注预防低血压,在新生儿酸碱结局方面至少不劣于去氧肾上腺素。

研究设计与样本

  • 多中心、随机、双盲、非劣效研究,纳入185例择期剖宫产产妇,比较腰麻后立即启动的去氧肾上腺素与间羟胺预防性输注。

主要发现

  • 脐动脉pH均值(SD)去氧肾上腺素组为7.28(0.06),间羟胺组为7.31(0.04),p=0.0002。
  • 估计平均pH差异(95%CI)为0.03(0.01-0.04),高于预设临床非劣效下界,并满足优效标准。
  • 脐动脉乳酸浓度去氧肾上腺素组为2.8(1.2)mmol.l-1,间羟胺组为2.3(0.7)mmol.l-1,p=0.0018。
  • Apgar评分组间无显著差异;去氧肾上腺素组低血压(收缩压<90%基线)发生率更高,间羟胺组高血压(>110%基线)及重度高血压(>120%基线)发生率更高。
  • 恶心、呕吐或产妇心动过缓发生率组间无显著差异。

关键数值与推荐

  • 去氧肾上腺素初始输注速度为50 μg.min-1,间羟胺初始输注速度为250 μg.min-1。
  • 低血压定义为收缩压<90%基线,高血压定义为收缩压>110%基线,重度高血压定义为收缩压>120%基线。

临床怎么用

  • 择期剖宫产腰麻后预防低血压可考虑间羟胺输注,但需警惕高血压及重度高血压风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Prophylactic vasopressor administration is commonly recommended to reduce maternal hypotension during spinal anaesthesia for caesarean section. Metaraminol has undergone limited investigation in obstetric anaesthesia for this purpose, particularly in comparison with phenylephrine. In this multicentre, randomised, double-blind, non-inferiority study, we compared prophylactic phenylephrine or metaraminol infusions, started immediately after spinal anaesthesia, in 185 women who underwent elective caesarean section. Phenylephrine was initially infused at 50 μg.min-1 , and metaraminol at 250 μg.min-1 . The primary outcome was the difference in umbilical arterial pH between groups; secondary outcomes included other neonatal acid-base measures, and maternal haemodynamic changes. The mean (SD) umbilical arterial pH was 7.28 (0.06) in the phenylephrine group vs. 7.31 (0.04) in the metaraminol group (p = 0.0002). The estimated mean (95%CI) pH difference of 0.03 (0.01-0.04) was above the pre-determined lower boundary of clinical non-inferiority, and also met the criterion for superiority. Umbilical artery lactate concentration was 2.8 (1.2) mmol.l-1 in the phenylephrine group vs. 2.3 (0.7) mmol.l-1 in the metaraminol group (p = 0.0018). Apgar scores did not significantly differ between groups. There was a higher incidence of hypotension, defined as systolic arterial pressure < 90% baseline, in the phenylephrine group; there was a higher incidence of hypertension and severe hypertension (systolic arterial pressure > 110% and > 120% baseline, respectively) in the metaraminol group. There was no significant difference between groups in the incidence of nausea, vomiting or maternal bradycardia. We conclude that, when used as an infusion to prevent hypotension after spinal anaesthesia for elective caesarean section, metaraminol is at least non-inferior to phenylephrine with respect to neonatal acid-base outcomes.

来源:Anaesthesia,查看原文。版权归原作者所有。

引用

  1. McDonnell NJ, Paech MJ, Muchatuta NA, et al. A randomised double-blind trial of phenylephrine and metaraminol infusions for prevention of hypotension during spinal and combined spinal-epidural anaesthesia for elective caesarean section. Anaesthesia. 2017. PMID: 28255987. doi:10.1111/anae.13836

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。